Leukemia & Lymphoma最新文献_第2页

Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network). 早期弥漫性大B细胞淋巴瘤患者的治疗方法：托斯卡纳区域淋巴瘤网络（RTL）的回顾性、多中心、现实研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-21 DOI: 10.1080/10428194.2025.2456094

Emanuele Cencini, Marianna Palazzo, Dimitri Dardanis, Giulia Lucco Navei, Lara Mannelli, Valentina Zoi, Bianca Mecacci, Benedetta Sordi, Giulia Cervetti, Serena Rosati, Luca Nassi, Monica Bocchia, Alberto Fabbri

{"title":"Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network).","authors":"Emanuele Cencini, Marianna Palazzo, Dimitri Dardanis, Giulia Lucco Navei, Lara Mannelli, Valentina Zoi, Bianca Mecacci, Benedetta Sordi, Giulia Cervetti, Serena Rosati, Luca Nassi, Monica Bocchia, Alberto Fabbri","doi":"10.1080/10428194.2025.2456094","DOIUrl":"10.1080/10428194.2025.2456094","url":null,"abstract":"Treatment strategies for early stage diffuse large B-cell lymphoma (ES-DLBCL) include R-CHOP, with a similar schedule to that used in advanced stage, or a reduced number of cycles followed by radiation therapy (RT). We retrospectively analyzed 179 ES-DLBCL patients, managed according to the clinical practice. Treatment regimens include chemoimmunotherapy 4-6 cycles +/- RT as consolidation. First-line therapy was R-CHOP/CHOP-like in 88.8% of cases. RT as consolidation was administered to 29.9% of cases. Complete response rate was 87.2%, median PFS and OS were not reached. IPI 2-3 and first-line regimen with 3-4 cycles of R-CHOP without RT were the 2 prognostic variables for OS in multivariate analysis. After a median follow-up of 48 months, 31 patients died (17.3%). We suggest that both R-CHOP 6 cycles and 3-4 cycles followed by RT as consolidation seem to be valid first-line regimens, while an abbreviated strategy without RT could be associated to inferior outcome.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1111-1120"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas. 阿仑单抗和剂量调整EPOCH-R治疗复发或难治性侵袭性b细胞淋巴瘤的2期研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-03 DOI: 10.1080/10428194.2025.2457553

Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai, Mark A Ahlman, Nicole Lucas, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson, Mark Roschewski

{"title":"Phase 2 study of alemtuzumab and dose-adjusted EPOCH-R in relapsed or refractory aggressive B-cell lymphomas.","authors":"Rahul Lakhotia, Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Sanjal Desai, Mark A Ahlman, Nicole Lucas, Seth M Steinberg, Elaine S Jaffe, Wyndham H Wilson, Mark Roschewski","doi":"10.1080/10428194.2025.2457553","DOIUrl":"10.1080/10428194.2025.2457553","url":null,"abstract":"Immune cells within the lymphoma tumor microenvironment promote immune evasion and are rational therapeutic targets. Alemtuzumab targets CD52 expressed on malignant B-cells and infiltrating nonmalignant T-cells. We evaluated the safety and efficacy of alemtuzumab with DA-EPOCH-R in 48 patients with relapsed/refractory aggressive B-cell lymphoma. Febrile neutropenia occurred in 18% of cycles and serious infections in 21% of patients. Responses were observed in 30 (62%) patients, including 12 (80%) patients with classical HL and 3 (75%) patients with T-cell/histiocyte-rich large B-cell lymphoma (THRLCL). Seventeen (35%) patients achieved complete responses, and 12 (25%) were bridged to consolidation. The 2-year progression-free survival (PFS) and overall survival were 22.1% (95% CI, 11.5-34.7%) and 45.2% (95% CI, 34.3-58.9%), respectively. The 2-year PFS for HL and THRLCL patients was 35% and 50%, respectively. Alemtuzumab can be safely combined with DA-EPOCH-R in relapsed/refractory aggressive B-cell lymphomas and can induce durable responses in patients with T-cell-rich microenvironments.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1088-1099"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. cerdulatinib是一种双脾酪氨酸激酶/janus激酶抑制剂，用于复发/难治性外周t细胞淋巴瘤的开放标签2a期研究结果。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-08 DOI: 10.1080/10428194.2025.2455489

Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye, Michael S Khodadoust, Javier Munoz, Paul A Hamlin, Youn H Kim, Ryan A Wilcox, Manish R Patel, Greg Coffey, Alison Innes, Andreas Betz, Jaymes Holland, Cristina B Guzman, Sonali M Smith

{"title":"Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.","authors":"Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye, Michael S Khodadoust, Javier Munoz, Paul A Hamlin, Youn H Kim, Ryan A Wilcox, Manish R Patel, Greg Coffey, Alison Innes, Andreas Betz, Jaymes Holland, Cristina B Guzman, Sonali M Smith","doi":"10.1080/10428194.2025.2455489","DOIUrl":"10.1080/10428194.2025.2455489","url":null,"abstract":"In this phase-2a study (NCT01994382), patients aged ≥18 years with relapsed/refractory peripheral T-cell lymphoma (PTCL; angioimmunoblastic T-cell lymphoma/T follicular helper [AITL/TFH], n = 29); PTCL-not otherwise specified [NOS], n = 11; and Other, n = 25) received 30 mg oral cerdulatinib, a reversible dual inhibitor of spleen tyrosine kinase and Janus kinase, twice daily in 28-day cycles until disease progression or unacceptable toxicity. Overall response rate (ORR) was 36.2% (12 complete responses [CR],9 partial responses [PR], and 14 stable disease); median time to response was 1.9 months. ORR was 51.9% for AITL/TFH (10 CR, 4 PR) and 31.8% for Other (2 CR, 5 PR); median duration of response was 12.9 and 5.3 months, respectively. The most common grade ≥3 treatment-emergent adverse events were asymptomatic amylase elevation (23.1%), anemia (20.0%), and asymptomatic lipase elevation (18.5%). These data suggest clinical activity and acceptable tolerability for cerdulatinib in patients with relapsed/refractory PTCL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1100-1110"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are we maintaining minimal residual disease in myeloma? 我们是否在骨髓瘤中维持最小残留病变？

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-21 DOI: 10.1080/10428194.2025.2455485

Mohammed A Aljama, Hasib M Sidiqi, Morie A Gertz

引用次数: 0

Indolent lymphoma: addressing the needs of survivors. 惰性淋巴瘤：解决幸存者的需求。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-28 DOI: 10.1080/10428194.2025.2456970

Pasquale L Fedele, Stephen Opat

{"title":"Indolent lymphoma: addressing the needs of survivors.","authors":"Pasquale L Fedele, Stephen Opat","doi":"10.1080/10428194.2025.2456970","DOIUrl":"10.1080/10428194.2025.2456970","url":null,"abstract":"Over the past two decades, there has been a continuous improvement in outcome for patients with indolent lymphoma (iNHL) resulting in a gradual accumulation of survivors. While life expectancy in the current era approaches that of the lymphoma-free population, patients continue to experience lifelong complications of the disease and its treatment affecting general health, emotional, psychological and social wellbeing, relationships, employment, finances, and fitness. Contemporary care models while suited to the management of lymphoma are often lacking when it comes to identification and management of these additional needs. Given improvements in physical survival achieved over the past decades, it is timely for us to focus on other issues affecting patient wellbeing including immunodeficiency and infection, second cancers, cardiovascular disease, bone health, psychological wellbeing, and sexual health. Many of these aspects are in the domain of the primary care physician; however, there is limited guidance on how these issues should be addressed. It is now time for us to engage our patients, their caregivers, and other healthcare providers in care aspects beyond the lymphoma diagnosis, so they can anticipate a rich and full life, free from both direct and indirect consequences of the lymphoma diagnosis.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1021-1035"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. GMALL-PH-01试验的最终分析：标准化疗联合达沙替尼一线治疗费城染色体阳性急性淋巴细胞白血病的II期研究。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-08 DOI: 10.1080/10428194.2025.2460737

Fabian Lang, Andreas Voss, Guido Kobbe, Christian Junghanss, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, Lisa Heberling, Vladan Vucinic, Boris Böll, Max Topp, Dieter Hoelzer, Hubert Serve, Nicola Goekbuget, Oliver G Ottmann, Heike Pfeifer

{"title":"Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.","authors":"Fabian Lang, Andreas Voss, Guido Kobbe, Christian Junghanss, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, Lisa Heberling, Vladan Vucinic, Boris Böll, Max Topp, Dieter Hoelzer, Hubert Serve, Nicola Goekbuget, Oliver G Ottmann, Heike Pfeifer","doi":"10.1080/10428194.2025.2460737","DOIUrl":"10.1080/10428194.2025.2460737","url":null,"abstract":"Imatinib (IMA) plus chemotherapy followed by allogeneic hematopoietic cell transplantation (HCT) is established treatment for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). We investigated the use of dasatinib (DASA) combined with intensive chemotherapy in ALL (18-55 years) first-line in a prospective, multicenter phase II trial by the GMALL study group. 140 mg DASA QD was used with a pediatric-based induction and consolidation chemotherapy according to GMALL 07/2003 protocol with recommended consecutive HCT. Nineteen of 20 planned patients were enrolled in 12 centers. The hematologic CR rate after induction was 79% with an overall MRD negativity rate of 62.5%. Six patients died during induction and two discontinued therapy. This regimen achieved deep molecular responses but was associated with a higher than expected early mortality (21%) and was stopped prematurely due to toxicities. The GMALL therefore adopted a combination of low intensity chemotherapy plus IMA as its current induction regimen.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1079-1087"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML. 慢性髓单细胞白血病临床、病理和分子特征的综合分析：与骨髓增生异常CMML相比，骨髓增生性CMML中ASXL1和NRAS突变频繁，突变负担更高。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-17 DOI: 10.1080/10428194.2025.2453093

Yoonseo Jeong

引用次数: 0

Polatuzumab vedotin extravasation injury: a case report. Polatuzumab vedotin外溢性损伤1例报告。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-01-25 DOI: 10.1080/10428194.2025.2456092

Sushila A Toulmin, Hana I Nazir, Jeremy S Abramson, Jacob D Soumerai, Esther E Freeman

引用次数: 0

Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia. 同种异体造血细胞移植治疗t前淋巴细胞白血病后白血病软组织复发。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-08 DOI: 10.1080/10428194.2025.2462950

Colin J Thomas, David Porter, Vivianna M Van Deerlin, Siddharth Bhattacharyya, Veronica Carvajal, Joseph Kim, Salvatore Priore, Guang Yang, James N Gerson, Stefan K Barta

引用次数: 0

Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement. 同种异体造血干细胞移植并发KMT2A::MLLT1重排的成人急性髓系白血病患者分离的中枢神经系统B淋巴/髓系胆管复发。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-06-01 Epub Date: 2025-02-10 DOI: 10.1080/10428194.2025.2460046

Yao Sun, Na Liu, Yingjie Liu, Jing Deng, Jiang Du, Liangding Hu

引用次数: 0